ASIT AIW ASIT biotech: Information on the Total Number of Voting Rights and Shares

Transparency directive : regulatory news

13/07/2018 17:45





THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,
DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA,
JAPAN OR ANY JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL. OTHER
RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT LEGAL NOTICE AT
THE END OF THIS ANNOUNCEMENT.




Regulatory News:



ASIT biotech (Paris:ASIT) (ASIT - BE0974289218), a clinical stage
biopharmaceutical company focused on the research, development and
future commercialization of breakthrough immunotherapy products for the
treatment of allergies, discloses the information required under article
15 of the law of 2 May 2007 regarding the disclosure of important
shareholdings in listed companies.



Denominator – modified on 13 July 2018 following a capital increase:




  • New shares issued following the capital increase: 28,930


  • Total number of shares with voting rights: 17,038,722


  • Total number of voting rights (=denominator): 17,038,722



Total number of shares with voting rights upon capital increase:
17,038,722



***



About ASIT biotech

ASIT biotech is a Belgian clinical stage
biopharmaceutical company focused on the development and future
commercialization of a range of breakthrough immunotherapy products for
the treatment of allergies. Thanks to its innovative ASIT+™ technology
platform, ASIT biotech is currently the only developer of allergy
immunotherapy (AIT) product candidates consisting of a unique mixture of
highly purified natural allergen fragments in an optimal size selection.
This innovation results in a short treatment, expected to improve
patient compliance and real-life effectiveness. ASIT biotech’s product
pipeline contains three novel ASIT+™ product candidates targeting
respiratory allergies with the highest prevalence (i.e. grass pollen:
gp-ASIT+™ and house dust mite: hdm-ASIT+™), and food allergies (peanut
allergy: pnt-ASIT+™). These products could significantly expand the
current immunotherapy market. The Company believes that its innovative
ASIT+™ platform is flexible and would be applicable across a range of
allergies.



ASIT biotech has a headcount of 26 staff members at its headquarters in
Brussels and a laboratory in Liège, Belgium.



Further information can be found at www.asitbiotech.com.



Forward-looking statements

All statements in this
announcement that do not relate to historical facts and events are
“forward-looking statements”. In some cases, these forward-looking
statements can be identified by the use of forward-looking terminology,
including the words “believes,” “estimates,” “anticipates,” “expects,”
“intends,” “may,” “will,” “plans,” “continue,” “ongoing,” “potential,”
“predict,” “project,” “target,” “seek” or “should” or, in each case,
their negative or other variations or comparable terminology or by
discussions of strategies, plans, objectives, targets, goals, future
events or intentions. Forward-looking statements include statements
regarding the Company’s intentions, beliefs or current expectations. By
their nature, forward-looking statements involve known and unknown risks
and uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future. Forward-looking
statements are not guarantees of future performance. Given these risks
and uncertainties, you should not rely on forward-looking statements as
a prediction of actual results. Any forward-looking statements are made
only as of the date of this announcement and, without prejudice to the
Company’s obligations under applicable law in relation to disclosure and
ongoing information, the Company does not intend, and does not assume
any obligation, to update the forward-looking statements set forth in
this announcement.



Legal notice

This announcement does not constitute, or form
part of, an offer or invitation to sell or issue, or any solicitation of
an offer to purchase or subscribe for shares of ASIT biotech SA (the
“Company” and the “Shares”). Any purchase of, subscription for or
application for, Shares to be issued in connection with the intended
offering should only be made on the basis of information contained in
the prospectus and any supplements thereto, as the case may be. This
announcement does not constitute a prospectus and the information
contained herein is for information purposes only and does not purport
to be full or complete. Investors should not subscribe for any Shares
except on the basis of the information contained in the prospectus that
the Company expects to publish after its approval by the Belgian
Financial Services and Markets Authority, and which can then be obtained
at the Company’s registered office and on www.asitbiotech.com



This announcement is not for distribution, directly or indirectly, in or
into the United States or to any U.S. person within the meaning of the
U.S. Securities Act of 1933, as amended (the “Securities Act”). The
Shares have not been and will not be registered under the Securities Act
and may not be offered or sold in the United States, except pursuant to
an exemption from the registration requirements of the Securities Act.
The Company has not registered, and does not intend to register, any
portion of the intended offering of Shares in the United States, and
does not intend to conduct a public offering of Shares in the United
States.



This announcement and the information contained herein are not for
publication, distribution or release in or into the United States,
Australia, Canada, Japan or any jurisdiction where to do so would
constitute a violation of the relevant laws of such jurisdiction.



The Company is responsible for the information contained in this press
release.








ASIT biotech


Company

Thierry Legon, Tel.: +32 2
264 03 90
CEO

investors@asitbiotech.com

or

Media
and Investor Relations - France


NewCap
Dusan Oresansky /
Pierre Laurent
Tel.: +33 1 44 71 94 92

asitbiotech@newcap.eu

or

Media
Relations - Belgium


Laure-Eve Monfort, Tel.: +32 2 290 90 93

monfort@comfi.be










Other stories

09/12/2018 22:42
09/12/2018 14:17
09/12/2018 02:22
09/12/2018 22:07
09/12/2018 22:57
09/12/2018 21:09
09/12/2018 20:48
09/12/2018 09:01
09/12/2018 22:41
09/12/2018 17:19
09/12/2018 00:17
08/12/2018 17:26
09/12/2018 16:01
09/12/2018 18:46
09/12/2018 13:31
08/12/2018 19:39
10/12/2018 00:05
09/12/2018 15:30
09/12/2018 10:00
09/12/2018 18:22
09/12/2018 23:42
10/12/2018 00:29
09/12/2018 17:38
08/12/2018 22:52
09/12/2018 19:00
09/12/2018 23:12
10/12/2018 01:06
09/12/2018 21:04
08/12/2018 16:25
09/12/2018 08:37
08/12/2018 03:24
09/12/2018 19:17
09/12/2018 23:12
09/12/2018 17:38
08/12/2018 08:30
09/12/2018 15:34